CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

"Medical Journeys" chart a path each step of the way for physicians ... anti-amyloid agent gained approval in January 2023: lecanemab (Leqembi). It became the first in the class to move from ...

The Freshwater Ecosystems Explorer offers what experts call an unprecedented look at the world’s lakes, rivers and wetlands, ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at up-to-date safety data on Leqembi (lecanemab) at its next meeting in ...

A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was totally ineffective in ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

The accelerated approval is based on phase 2 data demonstrating that Leqembi reduced the accumulation of amyloid in the brain, although interim results from the phase 3 CLARITY-AD study revealed a ...

NPR's Jon Hamilton has been talking to people who've taken these drugs, and today he has the story of one of the first patients to receive the drug now marketed as Leqembi. JON HAMILTON ...